1. Discovery of an Heparin-Binding Epidermal Growth Factor Domain Antibody from a Phage Library and Analysis of Its Inhibitory Effects in SKOV3 Cells.
- Author
-
Lü, Peng, Qiu, Songlin, Pan, Ye, Shi, Shenyan, Yu, Qian, Yu, Feng, Miao, Lianjun, Wang, Huiying, and Chen, Keping
- Subjects
- *
THERAPEUTIC use of immunoglobulins , *THERAPEUTIC use of proteins , *DISEASE progression , *VIRUSES , *OVARIAN tumors , *EPIDERMAL growth factor , *EPIDERMAL growth factor receptors , *INFLAMMATION , *CANCER patients , *GENES , *DESCRIPTIVE statistics , *RESEARCH funding , *HEPARIN - Abstract
Objective: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), which binds to the EGF receptor, plays an important role in the occurrence and development of inflammation in various diseases. HB-EGF mediates the progression of ovarian cancer and is associated with disease prognosis. Thus, a specific humanized antibody to HB-EGF with high affinity is important. Methods: In this study, a humanized domain antibody (VH) against HB-EGF was discovered through phage display technology. The domain antibody was expressed in HB2151 cells and purified from the supernatant using protein L, and were used to test the its effect in invasion and migration of ovarian cancer SKOV3. Results: A domain antibody against HB-EGF was discovered, with a dissociation constant of ∼30 nM. Functional assays indicated that the domain antibody inhibited the functions of HB-EGF in promoting invasion and migration of SKOV3 cells. Conclusions: The selected domain antibody is a potential tool for developing novel drugs or therapies to combat ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF